In The News News Releases Television Placements Print Placements
Research: Molecular Differences in Biothera β-Glucans
Impact Immune Cell Responses

EAGAN, MN — June 27, 2011 — New in vitro and in vivo studies of Biothera β-glucans published in the current issue of the journal Blood demonstrate the importance of molecular structure in designing effective immunotherapies, the company announced today.

The paper confirms research published in the April issue of Nature that found that differences in yeast-derived β-glucan structures determine their ability to bind to receptors on innate immune cells and the specific immune responses that result.

Biothera’s soluble and particulate β-glucans depend on different receptors to elicit their biological activities. The Dectin-1 pathway is essential for Biothera’s particulate β-glucan to mediate immune modulatory effects on dendritic cell activation, macrophage phagocytosis, and CD4 (TH1) and CD8 (Cytotoxic) T-lymphocyte activation. In contrast, Biothera’s soluble β-glucan is dependent on Complement Receptor binding to elicit neutrophil-mediated responses to antibody targeted cells and does not directly effect T cell activation.

“These data demonstrate how different β-glucan structures affect immunomodulatory mechanisms,” said principal investigator Jun Yan, M.D., Ph.D. of the Department of Medicine, Co-director of Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville School of Medicine in Louisville, Kentucky. “Biothera’s ability to produce and characterize these β-glucan compounds was critical to this research.”

“As demonstrated in previous research, ‘structure matters’ to β-glucan binding and initiation of differential immunomodulatory responses,” said William Grossman, M.D., Ph.D., Biothera senior vice president of Research & Development. “Our commitment to researching the biological mechanisms underpinning the activity of our compounds will lead to even more effective pharmaceuticals and food-grade ingredients.”

The paper is entitled, "Differential Pathways Regulating Innate and Adapative Anti-Tumor Immune Responses by Particulate and Soluble Yeast-derived β--Glucans." The research was conducted under the leadership of Dr. Yan.

About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company is commercializing its unique technology platform through two business groups. Biothera’s Pharmaceutical Group is conducting multiple clinical trials for the development of an immune modulating drug that mobilizes the innate immune system to fight most types of cancer. The company’s Healthcare Group is a leading provider of natural immune health ingredients for the functional food and beverage, dietary supplement, cosmetic and animal nutrition markets.

Contact:
David Walsh
VP Communications
Biothera, the Immune Health Company
651-256-4606 (direct)
dwalsh@biothera.com

 

Immune Health Basics products contain Wellmune WGP®


How does it work? Watch Video

 

training_date